Version 1
: Received: 9 May 2024 / Approved: 9 May 2024 / Online: 10 May 2024 (10:38:31 CEST)
How to cite:
Silva, R. C. L. D.; Machado, D. A.; Silva, C. R. L. D.; Figueira, H. A.; Freitas, D. V.; Vasconcelos, A. C. C. F. Analysis of the Direct Costs of Neuromyelitis Optica in a Brazilian Hospital. Preprints2024, 2024050632. https://doi.org/10.20944/preprints202405.0632.v1
Silva, R. C. L. D.; Machado, D. A.; Silva, C. R. L. D.; Figueira, H. A.; Freitas, D. V.; Vasconcelos, A. C. C. F. Analysis of the Direct Costs of Neuromyelitis Optica in a Brazilian Hospital. Preprints 2024, 2024050632. https://doi.org/10.20944/preprints202405.0632.v1
Silva, R. C. L. D.; Machado, D. A.; Silva, C. R. L. D.; Figueira, H. A.; Freitas, D. V.; Vasconcelos, A. C. C. F. Analysis of the Direct Costs of Neuromyelitis Optica in a Brazilian Hospital. Preprints2024, 2024050632. https://doi.org/10.20944/preprints202405.0632.v1
APA Style
Silva, R. C. L. D., Machado, D. A., Silva, C. R. L. D., Figueira, H. A., Freitas, D. V., & Vasconcelos, A. C. C. F. (2024). Analysis of the Direct Costs of Neuromyelitis Optica in a Brazilian Hospital. Preprints. https://doi.org/10.20944/preprints202405.0632.v1
Chicago/Turabian Style
Silva, R. C. L. D., Débora Viana Freitas and and Claudia Cristina Ferreira Vasconcelos. 2024 "Analysis of the Direct Costs of Neuromyelitis Optica in a Brazilian Hospital" Preprints. https://doi.org/10.20944/preprints202405.0632.v1
Abstract
Objective: To evaluate the direct costs of treating patients with neuromyelitis optica spectrum disorders (NMOSD) in outpatient care, from a hospital and Unified Health System (SUS) perspective. Methods: Observational study with data collection by microfunding, carried out with patients diagnosed with neuromyelitis optics, treated at a university hospital, in the city of Rio de Janeiro. Mann-Whitney tests were performed to measure cost differences between patient groups by disease severity and analysis perspective. Results: Nine individuals with a median age of 48 years (IQR 30 - 59 years) were included. The median total costs for patients with greater severity from the perspective of the SUS and the hospital were R$ 21,638.22 (IIQ: R$ 15,614.63; R$ 25,985.32) and R$ 32,094.11 (IIQ: R$ 25,610 .60; R$ 38,617.25) respectively. For patients with moderate severity the median was R$ 7,339.85 (IIQ: R$ 6,235.45; R$ 11,912.05) from the SUS perspective and R$ 11,505.80 (IIQ: R$ 7,339.85; R$ 22,424.76) from the perspective of the hospital, where the use of medications had a major impact. Conclusion: The main cost drivers were medicines, especially those used off-label, and procedures.
Keywords
neuromyelitis optica; measure cost; Unified Health System.
Subject
Public Health and Healthcare, Public Health and Health Services
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
,
